Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool December 17, 2004 Bill Mann	Fannie Mae's Institutional Arrogance Pity that Fannie's management decided to test the limits of an implied Federal guarantee. Even if the government did step in and back Fannie and Freddie paper, there's not a chance that it'd back the equity.
The Motley Fool February 24, 2005 Bill Mann	Fannie's Sweater Has a Loose Thread Guess what? The regulator's back at the door, and he's got more questions for Fannie Mae.
The Motley Fool June 2, 2005 Nick Baker	Fannie and Freddie Face New Rules The mortgage giants may get a tougher regulator, but Bush and Greenspan want more. Investors, take note.
The Motley Fool September 29, 2005 Rich Duprey	Feds Find Fraud at Fannie? Investigators find new, "pervasive" evidence of accounting violations at mortgage guarantor Fannie Mae. The stock plunged nearly 11% to a low of $41.71, a level not seen since 1997.
The Motley Fool June 1, 2005 Chuck Saletta	Where Angels Fear to Tread In the right situation, short-term corporate crises can provide superior long-term possibilities. Of course, investing in companies in crisis comes with risk.
The Motley Fool July 7, 2005 Chris Mallon	A Big Tobacco Bargain With its legal woes resolved, Altria looks undervalued among its peers.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
BusinessWeek June 12, 2006 Dawn Kopecki	It Looks Like Fannie Had Some Help Major players on the Street may be tied to the fiasco at the mortgage giant Fannie Mae.
Reason January 2005 Julian Sanchez	Fannie Business An investigation by the Office of Federal Housing Enterprise Oversight found that Fannie Mae systematically misapplied generally accepted accounting practices and manipulated earnings reports to maintain an aura of stability.
The Motley Fool October 6, 2004 Bill Mann	What Does Fannie Mae Do? Fannie Mae's charter calls on it to ensure that the mortgage market is awash in enough cash so that Americans face minimal problems in their dream of owning a home. But how? And why are its accounting problems such a big deal?
BusinessWeek May 20, 2010 Bob Van Voris	Big Tobacco's Many Days in Court Facing thousands of lawsuits in Florida, cigarette makers are crying foul.
The Motley Fool October 27, 2011 Jim Royal	I Can't Quit You, Big Tobacco Big Tobacco is being hit by challenges across the spectrum -- lawsuits, declining smoking rates, and new packaging rules -- but some companies have been able to claim victories of a sort.
The Motley Fool April 10, 2006 Rich Duprey	Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses.
The Motley Fool March 7, 2008 Brian Orelli	A Heavy Price for Wyeth and Pfizer They're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer.
The Motley Fool March 23, 2005 Chuck Saletta	Catching the Hot Potatoes Diversification can protect your portfolio from the worst of a company's stumbles.
The Motley Fool February 10, 2006 Tim Hanson	Good Stocks to Buy Now Put the market to work for you -- today: Altria... Abbot Labs... Bristol-Myers... Tootsie Roll... Pfizer... Coca-Cola... Merck...
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
U.S. Banker June 2008 Joseph Rosta	The Two-Step: As Reform Ebbs, Congress Doles Out More Rope Government-sponsored enterprises Fannie Mae and Freddie Mac are being given new powers by Congress in an effort to reinvigorate the jumbo-loan market.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
BusinessWeek December 5, 2005 Michael Orey	Presto: A New Vioxx Liability Estimate! Why analysts' reports shift wildly with every twist in litigation against Merck.
The Motley Fool April 7, 2005 Bill Mann	Cherry-Picking Fannie Fannie Mae is now accused of keeping its most promising loans and selling the rest. That's a shock. But is it a problem for mortgage-backed securities investors?
BusinessWeek September 5, 2005 Amy Barrett	The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come
The Motley Fool January 21, 2004	Seeing Nothin' But Fannie Fannie Mae's earnings doubled amid a housing boom. Surprised? Don't be.
The Motley Fool December 22, 2004 W.D. Crotty	Investors Still Buying Fannie Mae Fannie Mae's stock has traded up as much as 5% on news that the CEO and CFO have left the company and the auditors have been dismissed.
The Motley Fool June 30, 2004 Selena Maranjian	Cigarette Profits at Risk If you're an investor in tobacco, then you have some new cause for concern. Fewer teens are smoking, which may put pressure on tobacco profitability.
The Motley Fool October 6, 2005 Chuck Saletta	Waiting on Greatness Waiting is often the hardest part of investing. But it's also usually the most lucrative.
The Motley Fool November 16, 2007 Seth Jayson	Fannie Flunks Again A suspicious looking accounting change may cause everyone to pay for Fannie Mae's bad behavior, if it leads to a green light for the housing bailout plan proposed by Fed Chair Ben Bernanke.
The Motley Fool May 10, 2005	Fair Value, Explained Don't confuse a stock's price with its fair value.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool March 21, 2005 Slaughter & Durell	Stock Madness 2005: First Data vs. Fannie Mae Fannie is ripe for a turnaround, while First Data rides the e-payment wave. What's your call? Play "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness to choose.
The Motley Fool April 13, 2004 Ben McClure	Altria's Smoke Signals Even though cigarettes make you cough and splutter, that's no excuse to ignore tobacco stocks. Altria, the company formerly known as Philip Morris, is the giant among tobacco stocks.
The Motley Fool June 29, 2005 Shannon Zimmerman	The Trouble With Energy Stocks With investors chasing performance by pumping barrels of money into the sector -- always an excellent contrarian indicator -- it may be time to step off the energy gas pedal and head in the direction of market roads less traveled.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool October 9, 2006 Billy Fisher	Deep Value in Altria A class-action lawsuit against Philip Morris provides the perfect buying opportunity for its parent company. Investors, take note.
The Motley Fool December 10, 2004 Philip Durell	Contrary to Popular Opinion An interview with contrarian asset manager David Dreman whose Scudder-Dreman High Return Fund has returned 12.9% per year to investors over 15 years. On the face of it, Dreman uses a simple strategy to screen candidates for his funds.
The Motley Fool January 30, 2004 Bill Mann	Sallie Mae Faces Inquiry The SEC questions the student loan company over a measly $100k. Apparently.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool January 31, 2006 Rich Duprey	Too Big to Fail -- or File Mortgage guaranty giant Fannie Mae avoids delisting despite failing to file financials. Investors, take note.
National Real Estate Investor June 1, 2005 Parke Chapman	Reforming Fannie and Freddie Given the accounting scandals at both Fannie Mae and Freddie Mac, it's no great shock that the two companies are bracing for increased regulatory oversight. The question for players in the multi-family real estate industry is whether the reforms will cramp their style.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool November 18, 2004 Philip Durell	Hunting for Value: Part 1 How can you cultivate solid value investments?
The Motley Fool December 21, 2004 Chris Mallon	End of the Legal Tunnel An improving legal environment makes Altria's shares look extremely undervalued.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool January 19, 2005 Chuck Saletta	Why Value Wins How a disciplined, value-focused approach to investing can turn the odds in your favor.
The Motley Fool June 18, 2010 Rick Aristotle Munarriz	A Fool Looks Back News from last week: Blockbuster, Fannie Mae, and Freddie Mac... Sony and Microsoft E3 stars... Pfizer kicks drug from pipeline... CBOE goes public...
The Motley Fool December 14, 2004 Chuck Saletta	Lift Your Lamp for Value It might not seem evident, but there's a strong parallel between Lady Liberty's call and an investor's search for value. Both are looking to accept others' discards.
The Motley Fool January 2, 2004 Selena Maranjian	Philip Morris Cuts Prices Will the cigarette maker's price cuts for wholesalers help boost profits?